Advertisement

Foreword

Published:November 27, 2018DOI:https://doi.org/10.1016/j.ejim.2018.11.006
      Aging is a natural process leading to the progressive loss of physiological functions, increased inflammatory status, decreased naïve immune T-cell population, increased mutational events and epigenetic modifications resulting in an impaired health status. With the aging of the population, the number of older patients with hematologic disease will continue to increase. Since life expectancy for an 80 year-old patient can vary between 3 and 11 years according to his health status, it is of major importance to identify patients without irreversible comorbidities who have a significant life-expectancy and who would benefit most from the optimal treatment of the hematologic disease.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect